Phase 3Data readout

4D-150

Wet age-related macular degeneration

FDMT4D Molecular Therapeutics

Expected catalystJune 30, 2027Company guidance: Jun 30, 2027

Catalyst overview

Event details

Drug or asset: 4D-150
Development stage: Phase 3
Event type: Data readout
Indication: Wet age-related macular degeneration

Research signalsHigh management interest

Research summary

What is being tracked?

This catalyst tracks a Phase 3 data readout for 4D-150 in Wet age-related macular degeneration . The expected timing is based on the latest available company guidance and may change.

Development notes

4FRONT-1 & 4FRONT-2(Ph3) trials. 3/10/25- First patients enrolled in 4FRONT-1 trial. 7/2/25- 4FRONT-1 topline data now expected in H1 2027. 4FRONT-2 initiated in June 2025 with topline data in H2 2027. 11/10/25:- 4FRONT-1 >200 randomized; enrollment complete Q1 2026, topline H1 2027. 4FRONT-2 topline H2 2027. 02/09/26:- 4FRONT-1 enrollment completed (>500 randomized) in ~11 months; topline H1 2027 reiterated; 4FRONT-2 timelines unchanged. 03/18/26:- 4FRONT-1 enrollment completed; target 480 patients per Ph3 trial; topline H1 2027, 4FRONT-2 topline H2 2027. 05/07/26:- 4FRONT-1 randomization complete (N=523); topline H1 2027 reaffirmed. 4FRONT-2 enrollment completes H2 2026; topline H2 2027. 06/29/26:- 4FRONT-2 enrollment complete; final randomization Q3 2026. 4FRONT-1 topline H1 2027; 4FRONT-2 H2 2027. 07/18/26:- PRISM confirms 3E10 selected as 4FRONT Ph3 dose; topline timing unchanged. 08/13/26:- 4FRONT-1 topline data is expected in Q2 2027. 4FRONT-2 topline data is expected in H2 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

What is being tracked?

This catalyst tracks a Phase 3 data readout for 4D-150 in Wet age-related macular degeneration . The expected timing is based on the latest available company guidance and may change.